The Prognostic and Therapeutic Value of PD-L1 in Glioma
Glioma is the most common type of primary brain tumors. After standard treatment regimen (surgical section, radiotherapy and chemotherapy), the average survival time remains merely around 14 months for glioblastoma (grade IV glioma). Recent immune therapy targeting to the immune inhibitory checkpoin...
Saved in:
Main Authors: | Ruo Qiao Chen (Author), Feng Liu (Author), Xin Yao Qiu (Author), Xiao Qian Chen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
by: Li Chen, et al.
Published: (2022) -
Prognostic value and immune-infiltration pattern of FOXD3-AS1 in patients with glioma
by: Zhenhua Chen, et al.
Published: (2023) -
Expression of B7‐H3 and TIM‐3 in gastric‐type endocervical adenocarcinoma: prevalence, association with PD‐L1 expression, and prognostic significance
by: Yao Sun, et al.
Published: (2024) -
Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023) -
Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma
by: Siliang Chen, et al.
Published: (2022)